Literature DB >> 1928815

Pentoxifylline in the treatment of distal diabetic neuropathy.

S M Cohen1, T Mathews.   

Abstract

Painful diabetic distal sensory neuropathy is a disabling and common complication of diabetes mellitus. There is evidence that microvascular changes resulting in ischemia to the vasa nervorum may contribute to this problem. Pentoxifylline has been shown to improve circulation through partially occluded peripheral vessels and has been postulated to be of potential benefit. Forty adult type II diabetics were enrolled in a double-blind, placebo-controlled study utilizing pentoxifylline for six months. Visual analog scores, nerve conduction studies, and physical examinations were used to evaluate response to treatment. At the end of the six-month trial, there was no significant difference in the patients' pain between the pentoxifylline- and placebo-treated groups. The authors conclude that pentoxifylline is not useful in the treatment of painful distal diabetic neuropathy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1928815     DOI: 10.1177/000331979104200908

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  3 in total

1.  Rolipram and pentoxifylline combination ameliorates experimental diabetic neuropathy through inhibition of oxidative stress and inflammatory pathways in the dorsal root ganglion neurons.

Authors:  Mona Dastgheib; Seyed Vahid Shetab-Boushehri; Maryam Baeeri; Mahdi Gholami; Mohammad Yahya Karimi; Asieh Hosseini
Journal:  Metab Brain Dis       Date:  2022-08-04       Impact factor: 3.655

Review 2.  Management of painful diabetic neuropathy.

Authors:  P G Jensen; J R Larson
Journal:  Drugs Aging       Date:  2001       Impact factor: 4.271

3.  Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: A randomized trial.

Authors:  Frahad Hosseini; Abolfazl Mohammadbeigi; Mohammad Aghaali; Razieh Borujerdi; Mahmoud Parham
Journal:  J Res Med Sci       Date:  2019-10-25       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.